High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
This pilot phase I trial aims to investigate the efficacy and safety of high- and low-dose radiotherapy combined with programmed cell death-1 (PD-1) inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that have failed second-line immunotherapy or above.
Colorectal Liver Metastases
RADIATION: Radiation: High- and Low-dose radiotherapy|DRUG: PD-1 Inhibitors
Objective response rate (ORR), The proportion of patients showing complete or partial response of low-dose radiotherapy lesions and other metastatic lesions assessed by RECIST v1.1, 1,3,6, and 12 months after completion of radiotherapy
Progression-free survival (PFS), From the start of treatment to the date of progression or death, 12 months|Overall survival (OS), the time from the start of treatment to death from any cause, 12 months
Safety evaluation, NCI-CTCAE version 5.0 to assess adverse events (therapeutic toxicity), 12 months
This pilot phase I trial aims to investigate the efficacy and safety of high- and low-dose radiotherapy combined with programmed cell death-1 (PD-1) inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) that have failed second-line immunotherapy or above. 30 participants will be enrolled in this study. All will take part at Jiangsu Cancer Hospital.